BfArM - Federal Institute for Drugs and Medical Devices
Navigation and service
If you use the services of this provider, it is possible that usage data will be collected and, if necessary, stored in server logs.The BfArM has no influence on the type and scope of the transmitted or stored data. Go to LinkedIn
If you use the services of this provider, it is possible that usage data will be collected and, if necessary, stored in server logs.The BfArM has no influence on the type and scope of the transmitted or stored data. Go to LinkedIn
Risk information on medicinal products
In the following table you find all risk information in the topic medicinal products.
Active substance: telaprevir
The pharmaceutical manufacturer is sending out information on the occurrence of serious skin reactions associated with treatment with INCIVO®.
Active substance: cinacalcet
Important safety-relevant information regarding a fatal case with severe hypocalcaemia in a clinical study in children and adolescents.
Active substance: belatacept
The pharmaceutical manufacturer is sending out information on the increased occurrence of acute graft rejection under treatment with NULOJIX® (belatacept) associated with rapid corticosteroid taper in patients at high immunologic risk for acute rejection reactions.
Active substance: fentanyl
New warning regarding medicinal products (and generics) containing fentanyl and the possible occurrence of serotonin syndrome if used concomitantly with serotonergic medicines.
Active substance: botulinum toxin type B
Serious adverse events were observed in connection with NeuroBloc® if used outside the licensed indication ("off-label“).